Tirzepatide vs Liraglutide: side-by-side comparison
Tirzepatide (GIP/GLP-1 dual receptor agonist) and Liraglutide (GLP-1 receptor agonist) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Tirzepatide | Liraglutide |
|---|---|---|
| Therapeutic class | GIP/GLP-1 dual receptor agonist | GLP-1 receptor agonist |
| CAS | 2023788-19-2 | 204656-20-2 |
| ATC | A10BX16 | A10BJ02 |
| Molecular weight | 4813.5 g/mol | 3751.2 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Tirzepatide and Liraglutide share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Tirzepatide acts by a different mechanism than Liraglutide, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Tirzepatide: Tirzepatide binds with high affinity to the GIP receptor and to the GLP-1 receptor. Liraglutide: Liraglutide binds and activates the GLP-1 receptor in pancreatic beta and alpha cells, the central nervous system and the gastrointestinal tract.
Indications compared
Tirzepatide: Tirzepatide is approved in adults with type 2 diabetes mellitus, as monotherapy or in combination with other antidiabetic agents, to improve glycaemic control. Liraglutide: Liraglutide is approved in adults with type 2 diabetes mellitus, alone or in combination with other antidiabetic agents, to improve glycaemic control.
Safety profile
Tirzepatide: The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting, decreased appetite, constipation and abdominal discomfort, generally mild to moderate and most pronounced during dose escalation. Liraglutide: The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal discomfort, generally mild to moderate and most pronounced during the initial dose escalation.
Frequently asked questions
Is Tirzepatide better than Liraglutide? ▾
Tirzepatide and Liraglutide are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Tirzepatide and Liraglutide be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Tirzepatide
Products with Liraglutide
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.